Compare TRAK & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRAK | MDWD |
|---|---|---|
| Founded | 1990 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.2M | 162.2M |
| IPO Year | 1996 | 2013 |
| Metric | TRAK | MDWD |
|---|---|---|
| Price | $7.31 | $11.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $30.67 |
| AVG Volume (30 Days) | 66.3K | ★ 79.3K |
| Earning Date | 11-12-2026 | 11-19-2026 |
| Dividend Yield | ★ 1.08% | N/A |
| EPS Growth | ★ 11.43 | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $21,007,076.00 | N/A |
| Revenue This Year | $9.50 | $39.60 |
| Revenue Next Year | $10.00 | $34.34 |
| P/E Ratio | $18.85 | ★ N/A |
| Revenue Growth | ★ 4.84 | N/A |
| 52 Week Low | $6.94 | $11.84 |
| 52 Week High | $15.80 | $19.70 |
| Indicator | TRAK | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 34.91 | 39.47 |
| Support Level | $6.95 | $11.84 |
| Resistance Level | $9.06 | $14.06 |
| Average True Range (ATR) | 0.23 | 0.50 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 19.09 | 11.54 |
ReposiTrak Inc is a software-as-a-service (SaaS) company based in Murray, Utah, specializing in supply chain management solutions for retailers, suppliers, and wholesalers, prominently in the food industry. The company offers three main product suites: ReposiTrak Compliance Management, ReposiTrak Traceability Network, and ReposiTrak Supply Chain Solutions. These platforms help customers comply with food safety regulations, manage supplier compliance documentation, trace products through the supply chain, and optimize supply chain operations. The company derives revenue from five sources: (i) subscription fees, (ii) transaction-based fees, (iii) professional services fees, (iv) license fees, and (v) hosting and maintenance fees.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.